Chemomab Therapeutics and Scipher Medicine announced that the SEC approved their merger registration statement, with a shareholder vote scheduled for December 4, 2026. If approved, the merger will create a leading immunology precision medicine company, combining Scipher's AI platform and Chemomab's drug nebokitug, targeting rheumatoid arthritis. The combined company will be named Scipher Medicine Corporation and listed on Nasdaq under the ticker SCIP. The merger is expected to close in early 2027, with a Phase 2 trial for nebokitug planned to start in the first half of 2027.
Chemomab Therapeutics and Scipher Medicine's SEC registration statement approval is notable alongside today's Health-sector market activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 02, 2026 19:21 WIB: out of 150 priced US Health-sector stocks, 82 rose and 47 fell. Notable movers include MMED at USD 17.74 with a -2.95% change and a typical hold time of 13 days, MRVI at USD 8.03 up 2.82% with a 14-day hold, and BNGO at USD 1.18 up 2.61% with a 52-day hold time.
The global bio-based construction polymer market, valued at $18.2 billion in 2025, is projected to grow to $35 billion by 2033 at an 8.3% CAGR. Growth is fueled by rising demand for sustainable building materials that reduce greenhouse gas emissions ...
Annual Over-the-Air (OTA) software updates for software-defined vehicles (SDVs) are projected to reach over 2 billion globally by 2035, up from 546 million in 2025, driven by rising SDV sales and advanced vehicle software platforms. Level 3 and above...
Fram Wind Solutions AS, a joint venture partly owned by BW Offshore, secured a NOK 1.94 billion grant from Enova to develop a floating offshore wind project featuring two 18.5 MW turbines, the largest globally, with a combined capacity of 37 MW. The ...
Thailand's textile market is projected to grow from USD 4.97 billion in 2026 to USD 5.39 billion by 2032, at a CAGR of 1.31%. Growth is fueled by domestic fiber production, machinery upgrades, and rising demand for faster garment replenishment, espec...
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
